Fig. 2: Kaplan-Meier survival curves for patients who received upfront JAKi vs. HCT. | Bone Marrow Transplantation

Fig. 2: Kaplan-Meier survival curves for patients who received upfront JAKi vs. HCT.

From: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study

Fig. 2

Yellow curves represent OS probability of patients who received upfront JAKi and blue curves represent that of patients who received upfront HCT for (a) the entire cohort of 302 patients with MF DIPSS int-1 or higher, (b) 126 patients with DIPSS int-1, and (c) 176 patients with DIPSS int-2 or high risk.

Back to article page